- Vericel Corporation (VCEL, Financial) to participate in the Truist Securities MedTech Conference on June 17, 2025.
- The presentation, in a fireside chat format, will begin at 9:20 a.m. ET.
- Investors can access the live webcast through Vericel's Investor Relations website.
Vericel Corporation (VCEL), a leader in advanced therapies for sports medicine and severe burn care, has announced its participation in the upcoming Truist Securities MedTech Conference. The company will engage in a fireside chat scheduled for Tuesday, June 17, 2025, at 9:20 a.m. ET. This presentation offers an opportunity for investors to gain insights into Vericel's operations and strategic advancements in the medical technology sector.
Interested investors can access the webcast through the Investor Relations section of Vericel's website at investors.vcel.com. This platform will allow stakeholders to explore Vericel's innovative contributions to medical biotechnology, including their offerings such as MACI, Epicel, and NexoBrid.
Vericel (VCEL, Financial) has positioned itself as a significant player in the biotechnology industry, with a market capitalization of $2.04 billion and a strong institutional ownership of 106.6%. The company's products, such as MACI® for cartilage repair and Epicel® for burn care, underscore its commitment to delivering solutions that repair injuries and restore lives.
